Thyroid eye disease, commonly referred to as TED, is an autoimmune condition characterized by inflammation, growth, and damage to tissues around and behind the eyes.

Most often, TED occurs when the thyroid gland is overactive. In rare cases, TED can occur in people who have normal or underactive thyroids. An estimated 85% of people with TED will also have Graves’ disease. Given the close association between these two autoimmune conditions, TED is sometimes referred to as Graves’ eye disease, Graves’ ophthalmopathy, and Graves’ orbitopathy.

Overview of Thyroid Eye Disease

View

What are Common Symptoms of TED?

Not everyone living with TED will experience the same symptoms, and the impact of each symptom can vary by individual. Common symptoms include:

Previous Next

Dry eyes
Redness of
the eyes
Pain in and
around the eyes
Eyeline
retraction
Bulging eyes,
known as proptosis
Sensitivity to light
Double vision,
known as diplopia
Swelling of the eyes and surrounding tissue
Damage to eyes and, in severe cases, potential loss of sight

In addition to the physical symptoms of TED, people often experience significant psychosocial complications, including depression, anxiety, self-consciousness, disconnection from friends and family as well as the inability to work and perform basic daily activities.

Understanding the TED Journey

Understanding the TED Journey graphic

Clinical Studies in Thyroid Eye Disease

Viridian Therapeutics is focused on engineering and developing potential best-in-class medicines for people living with autoimmune and rare diseases. Viridian is studying multiple candidates in clinical studies for TED.

THRIVE

Active Thyroid Eye Disease

Global Phase 3 trial to evaluate the efficacy and safety of VRDN-001 in patients with active TED

THRIVE-2

Chronic Thyroid Eye Disease

Global Phase 3 trial to evaluate the efficacy and safety of VRDN-001 in patients with chronic TED

REVEAL-1

Active Thyroid Eye Disease

Global phase 3 trial to evaluate the efficacy and safety of VRDN-003 administered subcutaneously in patients with active TED

REVEAL-2

Chronic Thyroid Eye Disease

Global phase 3 trial to evaluate the efficacy and safety of VRDN-003 administered subcutaneously in patients with chronic TED

For more information on our ongoing clinical studies for people affected by TED, please visit clinicaltrials.gov or speak with a healthcare provider.

Connect with the Thyroid Eye Disease Community

The following organizations offer resources and information on TED:

Links to sites outside of this website are provided as a resource to the visitor. The web pages and their content are independently maintained by the third-party organizations listed above. Viridian does not specifically endorse any organization or the content on its website. If you would like your organization to be included in this list, please reach out to us at patientadvocacy@nullviridiantherapeutics.com.

By providing your information, you agree to allow Viridian to collect the name and email address provided and to be contacted by Viridian and its partners using this information.

Connect with Viridian’s Patient
Advocacy & Engagement Team

To learn more about Viridian’s TED clinical development program or to connect with a member of our Patient Advocacy & Engagement team, please email patientadvocacy@nullviridiantherapeutics.com.